You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Details for New Drug Application (NDA): 216017


✉ Email this page to a colleague

« Back to Dashboard


NDA 216017 describes IOMERVU, which is a drug marketed by Bracco and is included in two NDAs. Additional details are available on the IOMERVU profile page.

The generic ingredient in IOMERVU is iomeprol. There is one drug master file entry for this compound. Additional details are available on the iomeprol profile page.
Summary for 216017
Tradename:IOMERVU
Applicant:Bracco
Ingredient:iomeprol
Patents:0
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 216017
Generic Entry Date for 216017*:
⤷  Get Started Free
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength25GM IODINE/100ML (250MG IODINE/ML)
Approval Date:Nov 27, 2024TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 27, 2029
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength15GM IODINE/50ML (300MG IODINE/ML)
Approval Date:Nov 27, 2024TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 27, 2029
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength30GM IODINE/100ML (300MG IODINE/ML)
Approval Date:Nov 27, 2024TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 27, 2029
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links